[Effect of gestagen therapy upon estradiol- and progesterone-receptor-level and 17beta-hydroxysteroid dehydrogenase in human endometrial adenocarcinoma (author's transl)].
Oestradiol was converted to oestrone about ten time more rapidly by subcellular fractions of normal human endometrium of the secretory phase than by tissue of the proliferative phase. In subcellular fractions of endometrial carcinoma the 17beta-hydroxysteroid dehydrogenase (17beta-HSD) activity decreased with decreasing differentiation of the tumour. Most of the 17beta-HSD activity was located in mitochondrial and microsomal fractions of both normal and neoplastic endometrium. After treatment of patients with gestagens only the well differentiated carcinomata significantly increased in 17beta-HSD activity demonstrating that the hormonal stimulus leads to similar effects on the 17beta-HSD activity as in normal endometrium. Furthermore quantitative aspects of the in vitro binding of 3H-oestradiol and 3H-progesterone to receptor components from normal endometrium and endometrial carcinoma cytoplasmic fractions have been studied. In normal tissue the number of cytoplasmic binding sites for both oestradiol and progesterone varied dramatically during the menstrual cycle: number of oestradiol binding sites were highest during the proliferative phase and fell during the secretory phase; for progesterone site the contrary was the case. In all endometrial carcinomata high oestradiol binding activity was observed. In contrast the number of progesterone sites in the tumours was related to the state of differentiation, which paralled the progestional sensitivity of these tumours.
D000230:Adenocarcinoma / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism*; D002454:Cell Differentiation; D004717:Endometrium / Q000378:metabolism; D004958:Estradiol / Q000378:metabolism*; D005260:Female; D006801:Humans; D006913:Hydroxysteroid Dehydrogenases / Q000378:metabolism*; D008598:Menstruation; D011374:Progesterone / Q000378:metabolism*; D045167:Progesterone Congeners / Q000627:therapeutic use*; D011956:Receptors, Cell Surface / Q000187:drug effects; D013347:Subcellular Fractions / Q000378:metabolism; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism*
D045167:Progesterone Congeners; D011956:Receptors, Cell Surface; D011374:Progesterone; D004958:Estradiol; D006913:Hydroxysteroid Dehydrogenases
Oestradiol- und Progesteron-bindende Receptoren sowie 17 beta-Hydroxysteroiddehydrogenase in Endometriumcarcinomen der Frau vor und nach Gestagen-Behandlung